Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

DAIICHI S : Notice on Details of the Share Options

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2011 | 10:20am CET
For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, Corporate Officer, Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

http://www.daiichisankyo.com/Notice on Details of the Share OptionsTOKYO, Japan (July 12, 2011) Daiichi Sankyo Company, Limited has announced that the subscription amount and other details of its No.5 share options were decided today. As previously announced, the Board of Directors had reached a decision on June 27, 2011 to issue the said share remuneration-type stock options (share options) to remunerate Directors (excluding Outside Directors) and Corporate Officers

1. Name of share options

Daiichi Sankyo Company, Limited No. 5 share options

2. Total number of share options

2,328 share options (100 shares per one share option) Breakdown

Six (6) Directors: 1,102 share options

Eighteen (18) Corporate Officers: 1,226 share options

3. Subscription amount for share options

111,200 yen per share option

(1,112 yen per share)

Reference

Date of Board of Directors resolution: June 27, 2011

###
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DAIICHI SANKYO COMPANY, LI
12/02 DAIICHI SANKYO : U.S. FDA Grants Fast Track Designation for HER2-Targeting Antib..
11/30 DAIICHI SANKYO : Announces Japanese Research Partners Selected for 2016 TaNeDS C..
11/21 DAIICHI SANKYO WEBCAST PRESENTATION : dbVIC - Deutsche Bank ADR Virtual Investo..
11/21 SUN PHARMACEUTICAL INDUSTRIES : Bright prospects
11/11 DAIICHI SANKYO : to present at the dbVIC - Deutsche Bank ADR Virtual Investor Co..
11/10 PIERIS PHARMACEUTICALS, INC. (NASDAQ : PIRS) Files An 8-K Reports Financial Resu..
11/10 International companies to host live webcasts at Deutsche Bank's Depositary R..
11/03 DAIICHI SANKYO : Mylan Launches First Generics of Benicar® and Benicar HCT® Tabl..
11/03 DAIICHI SANKYO : Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 T..
11/03 DAIICHI SANKYO : Ajanta pharma's bp drug in us
More news
Sector news : Pharmaceuticals - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11/07 FDA OKs Teva's generic version of blood pressure med Tribenzor
11/03 6 Ways To Profit From This Looming Disaster
10/22 ArQule Is Undervalued Going Into Catalyst Events
10/11 Daiichi Sankyo's late-stage study of leukemia candidate quizartinib underway
10/05 Free-For-All For Twitter
Advertisement
Financials ( JPY)
Sales 2017 924 537 M
EBIT 2017 -
Net income 2017 69 932 M
Finance 2017 298 375 M
Yield 2017 2,90%
P/E ratio 2017 22,93
P/E ratio 2018 24,01
EV / Sales 2017 1,53x
EV / Sales 2018 1,58x
Capitalization 1 710 135 M
More Financials
Chart DAIICHI SANKYO COMPANY, LI
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Full-screen chart
Technical analysis trends DAIICHI SANKYO CO...
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 2 400  JPY
Spread / Average Target -0,50%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joji Nakayama President, CEO & Representative Director
Kentaro Takamura Vice President-Finance & Accounting Department
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Masahiko Ohtsuki Executive Officer & Senior Manager-Research
Kazunori Hirokawa Representative Director, VP & GM-Administration
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY..-3.25%15 061
JOHNSON & JOHNSON9.00%304 591
PFIZER INC.-2.01%191 942
ROCHE HOLDING LTD.-19.61%188 878
NOVARTIS AG-19.07%178 737
MERCK & CO., INC.15.85%168 544
More Results